Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 416 | 54 | 358 |
| Samples | 373 | 50 | 319 |
| Peptides | 249 | 33 | 225 |
Function
IRF4 · Interferon regulatory factor 4
The protein encoded by this gene belongs to the IRF (interferon regulatory factor) family of transcription factors, characterized by an unique tryptophan pentad repeat DNA-binding domain. The IRFs are important in the regulation of interferons in response to infection by virus, and in the regulation of interferon-inducible genes. This family member is lymphocyte specific and negatively regulates Toll-like-receptor (TLR) signaling that is central to the activation of innate and adaptive immune systems. A chromosomal translocation involving this gene and the IgH locus, t(6;14)(p25;q32), may be a cause of multiple myeloma. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Aug 2010].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000380956 | Q15306 | 416 | 249 |
Gene Properties
Recurrent Mutations
All 249 amino-acid changes on canonical ENST00000380956 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in IRF4 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in IRF4 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Hodgkins Lymphoma | 3/16 19% | 2/122 2% |
| Endometrial Carcinoma | 4/42 10% | 18/612 3% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| B-Cell Non-Hodgkins Lymphoma | 5/88 6% | 77/2534 3% |
| Plasma Cell Myeloma | 3/44 7% | 7/305 2% |
| Gastric Carcinoma | 2/74 3% | 23/1809 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 9/810 1% |
| Other Solid Cancers | 3/94 3% | 17/1515 1% |
| Esophageal Carcinoma | 0/23 0% | 9/769 1% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 17/1390 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Melanoma | 2/210 1% | 16/1899 1% |
| Glioma | 2/52 4% | 15/2127 1% |
| Colorectal Carcinoma | 5/143 4% | 21/3239 1% |
| Ovarian Carcinoma | 2/109 2% | 6/998 1% |
| Biliary Tract Carcinoma | 0/54 0% | 6/950 1% |
| Bladder Carcinoma | 1/58 2% | 5/956 1% |
| Neuroendocrine Tumour | 2/154 1% | 2/577 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 9/1592 1% |
| Head and Neck Carcinoma | 0/85 0% | 9/1574 1% |
| Hepatocellular Carcinoma | 0/46 0% | 10/2210 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Non-Cancerous | 1/104 1% | 3/830 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Other Blood Cancers | 2/61 3% | 9/2725 0% |
| Prostate Carcinoma | 2/13 15% | 4/2105 0% |
| Kidney Carcinoma | 0/85 0% | 5/1862 0% |
| Breast Carcinoma | 2/144 1% | 5/3264 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 4/2550 0% |
Mutation Distribution
Where IRF4 is mutated · all tissues, split by cell line vs tissue
How many mutations in IRF4 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 416 mutations in IRF4
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|